Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-month open-label extension study of lisdexamfetamine in adults with binge eating disorder
2012-003313-34Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lisdexamfetamine in binge eating disorder (BED), sponsored by Takeda. Primary endpoint: Treatment-emergent adverse events. Started Jan 2013; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on 2012-003313-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003313-34.